3 Hot Stocks You Bought Today

LONDON -- This morning, pharmaceutical giant GlaxoSmithKline (LSE: GSK.L  ) was the fourth-most popular purchase by stockbroker TD Direct Investing's individual clients between the market's opening and noon.

Why? A 2% drop in the share price gives a clue: Institutional investors have been selling, it turns out. Consequently, private buyers have been stepping in this morning to grab a piece of this high-yielding drugs-to-toothpaste global business that handily pays its dividends quarterly, and which is presently offering a prospective yield of 5.2% on a forecast P/E of 12.

And the reason for the institutional sell-off? A downgrade by Morgan Stanley, it seems, which expressed a preference for AstraZeneca, citing concerns over margins.

The fifth- and sixth-most popular picks this morning by the private clients of the stockbroker are two companies bracketed together in a merger play -- respectively, Xstrata (LSE: XTA.L  ) and Glencore (LSE: GLEN.L  ) .

The reason? There's been overnight news regarding the proposed terms of the deal, which has been stalled by sovereign wealth fund Qatar Holding, 12% owner of Xstrata. A Glencore shareholders' meeting to discuss the deal has been canceled, and the offered price for each Xstrata share has been raised from 2.8 Glencore shares to 3.05 shares.

Sensing a bargain, private investors have piled in. Will they be disappointed? Time will tell.

Finally, what are super-investors Neil Woodford and Warren Buffett buying today? We can't tell you that, but we can tell you the names of the shares that they've been buying in the recent past -- and why they've been buying them.

So download this free report to discover the shares that interest Neil Woodford right now, and this free report to learn the name of the British share that Warren Buffett has been buying recently. There's no obligation, and the reports can be in your inbox in seconds.

Are you looking to profit as a long-term investor? "10 Steps To Making A Million In The Market" is the latest Motley Fool guide to help Britain invest. Better. We urge you to read the report today -- while it's still free and available.

Investing ideas from Malcolm Wheatley:

Malcolm owns shares in GlaxoSmithKline and AstraZeneca but has no disclosable interest in any other of the shares mentioned. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Disclaimer: The TD Direct Investing (www.tddirectinvesting.co.uk) list of Top Ten Buys should not be taken as a recommendation to buy or sell any particular bond or stock, and is not intended as any form of advice. Instead, it is simply an indication of the general buying trends among TD Direct Investing customers during the period stated.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 07, 2012, at 11:56 AM, popsranola wrote:

    Glaxo good buying opportunity with safe dividends......Same as Aztra Zeneca....wow.......Imperial Tabbacoo.....good buying opportunity with fat and meaty dividends....he...he...he...he...Fat Dividends......the is good......

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2009574, ~/Articles/ArticleHandler.aspx, 10/21/2014 11:53:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement